Seasoned investor and operator focused on growth-stage companies. Scott McMillan is known for structuring growth and turnaround investments, active board engagement and driving revenue-led operational improvements across technology and healthcare sectors. Prior experience spans corporate development, private equity and hands-on operating roles; typical remit includes M&A, strategic planning and CEO-level support. Engages with institutional investors and management teams on exits, recapitalizations and scale-up strategies.
Seasoned investor and operator focused on growth-stage companies. Scott McMillan is known for structuring growth and turnaround investments, active board engagement and driving revenue-led operational improvements across technology and healthcare sectors. Prior experience spans corporate development, private equity and hands-on operating roles; typical remit includes M&A, strategic planning and CEO-level support. Engages with institutional investors and management teams on exits, recapitalizations and scale-up strategies.
Prioritizes growth-stage and turnaround opportunities where operational intervention accelerates revenue and margin expansion. Focuses on technology and healthcare businesses with clear product-market fit, scalable go-to-market models and defensible market positions. Employs hands-on capital allocation: minority or control investments, structured recapitalizations and M&A to derisk paths to exit. Active board partnership with CEOs, emphasizing commercial playbooks, talent upgrades and data-driven KPIs. Time horizon is medium-term (3–7 years) with pragmatic risk controls and performance-aligned incentives.
Prioritizes growth-stage and turnaround opportunities where operational intervention accelerates revenue and margin expansion. Focuses on technology and healthcare businesses with clear product-market fit, scalable go-to-market models and defensible market positions. Employs hands-on capital allocation: minority or control investments, structured recapitalizations and M&A to derisk paths to exit. Active board partnership with CEOs, emphasizing commercial playbooks, talent upgrades and data-driven KPIs. Time horizon is medium-term (3–7 years) with pragmatic risk controls and performance-aligned incentives.
| Trades 337 | Longs Won 252/337 74% | Profit Factor 42.74 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $745,469.91 |
| Average Win $201,577.85 | Best Trade (Jul 16) $10.36M | Sharpe Ratio -81.38 |
| Average Loss -$13,982.46 | Worst Trade (Jun 29) -$190,918.91 | Z-Score 11.2 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 1d | Expectancy $147,208.04 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 13,699 | 12,329 | 10,959 | 9,589 | 8,219 | 6,849 | 5,479 | 4,110 | 2,740 | 1,370 |